ACI Group has partnered with DolCas Biotech to distribute its nutraceutical ingredients range to the UK market.
Through the agreement, ACI Group will be responsible for the marketing and distribution of at least five of DolCas' clinically-backed functional ingredients, including:
- Curcugen: A whole turmeric extract that claims to deliver 39x more curcuminoids to the blood plasma
- Morikol: A marine collagen standardised to 15% that's designed to boost skin and joint health
- NitrateBurst: A green leaf spinach extract formulated to fortify heart health
- BergacynFF: A combination neutraceutical containing bergamot citrus and Cynara cardunculus extracts, which has been clinically proven to support normal fat levels in the liver, while also promoting healthy weight loss
- Fortiquin: A blend of L-arginine and extracts of mucuna, fenugreek, ashwagandha and artichoke designed to support men's sexual vitality
- MMP50: A whole mussel extract that can offer immune-boosting and pain-diminishing effects
DolCas claim that the high potency of Morikol and NitrateBurst can enable brands to offer their collagen and phytonitrate supplements in tablet or capsule forms.
This differs from the traditional powders, which require a user to take up to 20g to get an effective daily dose.
DolCas' collaboration with ACI Group will now allow UK-based dietary supplement manufacturers to utilise DolCas' premium functional ingredients in its formulations.
CEO of ACI Group, Karsten Smet, commented: "This partnership with DolCas Biotech opens doors for our customers to create truly differentiated products that command attention. In today's competitive market, brands and their formulators need ingredients that not only work in a targeted way to address critical health priorities but substantiates those claims."
"DolCas Biotech's clinically proven range — with focus on superior bioavailability and potency — supports the development of innovative formulations that meet consumer demands for efficacy and ease of use. We look forward to supplying these ingredients to our health and nutrition customers across the UK and helping to usher in the next generation of nutraceutical solutions."
KG Rao, Founder & CEO at DolCas Biotech, added: "We're delighted to partner with ACI Group to introduce our innovative ingredients to the UK market. Today's nutraceutical market is all about building trust; consumers are increasingly engaged, but equally sceptical in their search for products that are effective and safe."
"We are intentional in our efforts to develop clinically researched ingredients that intelligently meet at the crossroads of high quality and optimised processing. The ACI Group is an experienced and established player in the functional ingredient market, making them a well-matched distribution partner for us."
